Literature DB >> 8589035

Frequent mutations of CDKN2 in primary pancreatic adenocarcinomas.

D Bartsch1, D W Shevlin, W S Tung, O Kisker, S A Wells, P J Goodfellow.   

Abstract

The gene encoding the cell-cycle regulatory protein p16, CDKN2, is localized on chromosome band 9p21. CDKN2 is frequently deleted or mutated in a variety of tumor cell lines, including pancreatic cancer cell lines and xenografts, as well as in some primary tumors. We examined 32 primary pancreatic adenocarcinomas for CDKN2 mutations and for loss of heterozygosity of 9p21 sequences to assess the role of CDKN2 in pancreatic carcinogenesis. Single-strand conformation variant analysis (SSCV) and direct sequencing of the variants revealed somatic CDKN2 mutations in 11 of 32 tumors (five frame-shift mutations, five nonsense mutations, and one missense mutation). One tumor appeared to be characterized by homozygous deletion of CDKN2. These results suggest that CDKN2 plays an important role during tumorigenesis or tumor progression in a significant proportion of pancreatic adenocarcinomas.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8589035     DOI: 10.1002/gcc.2870140306

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  13 in total

Review 1.  The CDKN2A (p16) gene and human cancer.

Authors:  W D Foulkes; T Y Flanders; P M Pollock; N K Hayward
Journal:  Mol Med       Date:  1997-01       Impact factor: 6.354

2.  p16INK4a is a prognostic marker in resected ductal pancreatic cancer: an analysis of p16INK4a, p53, MDM2, an Rb.

Authors:  Berthold Gerdes; Annette Ramaswamy; Andreas Ziegler; Sven A Lang; Michael Kersting; Renate Baumann; Anja Wild; Roland Moll; Matthias Rothmund; Detlef K Bartsch
Journal:  Ann Surg       Date:  2002-01       Impact factor: 12.969

3.  Genetic progression and divergence in pancreatic carcinoma.

Authors:  M Yamano; H Fujii; T Takagaki; N Kadowaki; H Watanabe; T Shirai
Journal:  Am J Pathol       Date:  2000-06       Impact factor: 4.307

Review 4.  Molecular diagnosis of pancreas carcinoma.

Authors:  T M Chu
Journal:  J Clin Lab Anal       Date:  1997       Impact factor: 2.352

5.  Molecular analysis of microdissected tumors and preneoplastic intraductal lesions in pancreatic carcinoma.

Authors:  E Heinmöller; W Dietmaier; H Zirngibl; P Heinmöller; W Scaringe; K W Jauch; F Hofstädter; J Rüschoff
Journal:  Am J Pathol       Date:  2000-07       Impact factor: 4.307

6.  Genetic progression and heterogeneity in intraductal papillary-mucinous neoplasms of the pancreas.

Authors:  H Fujii; M Inagaki; S Kasai; N Miyokawa; Y Tokusashi; E Gabrielson; R H Hruban
Journal:  Am J Pathol       Date:  1997-11       Impact factor: 4.307

7.  Distribution of cholecystokinin-B receptor genotype between patients with pancreatic cancer and controls and its impact on survival.

Authors:  Jill P Smith; David C Whitcomb; Gail L Matters; Randall E Brand; Jiangang Liao; Yu-Jing Huang; Marsha L Frazier
Journal:  Pancreas       Date:  2015-03       Impact factor: 3.327

Review 8.  Genetic alterations in pancreatic cancer.

Authors:  Muhammad Wasif Saif; Lena Karapanagiotou; Kostas Syrigos
Journal:  World J Gastroenterol       Date:  2007-09-07       Impact factor: 5.742

9.  Genome-wide characterization of pancreatic adenocarcinoma patients using next generation sequencing.

Authors:  Winnie S Liang; David W Craig; John Carpten; Mitesh J Borad; Michael J Demeure; Glen J Weiss; Tyler Izatt; Shripad Sinari; Alexis Christoforides; Jessica Aldrich; Ahmet Kurdoglu; Michael Barrett; Lori Phillips; Hollie Benson; Waibhav Tembe; Esteban Braggio; Jeffrey A Kiefer; Christophe Legendre; Richard Posner; Galen H Hostetter; Angela Baker; Jan B Egan; Haiyong Han; Douglas Lake; Edward C Stites; Ramesh K Ramanathan; Rafael Fonseca; A Keith Stewart; Daniel Von Hoff
Journal:  PLoS One       Date:  2012-10-10       Impact factor: 3.240

10.  Molecular Biologic Approach to the Diagnosis of Pancreatic Carcinoma Using Specimens Obtained by EUS-Guided Fine Needle Aspiration.

Authors:  Kiyohito Kato; Hideki Kamada; Takayuki Fujimori; Yuuichi Aritomo; Masahiro Ono; Tsutomu Masaki
Journal:  Gastroenterol Res Pract       Date:  2012-11-08       Impact factor: 2.260

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.